Eisai Predicts "Mayhem" For Kisplyx After NICE Finally Okays Halaven

On the basis of its experience with Halaven, Eisai is predicting that its kidney cancer drug Kisplyx will face a difficult journey getting the OK from NICE, England's health technology appraisal institute.

Rethink

NICE, the health technology appraisal body for England and Wales, has finally okayed Eisai Europe Ltd.'s breast cancer drug Halaven (eribulin), five years after it was first launched in the UK.

While the company will of course welcome the move, it says that in light of Halaven's long journey to routine...

More from Approvals

More from Product Reviews